NDLI: Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method

Please wait, while we are loading the content...

Application of the Dispersion Model for Description of the Outflow Dilution Profiles of Noneliminated Reference Indicators in Rat Liver Perfusion Studies

Characterization of the Dose-Dependent Time of Peak Effect in Indirect Response Models

Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients

Pitfalls in Pharmacokinetic Multicompartment Analysis

Announcements ( Journal of Pharmacokinetics and Pharmacodynamics , Volume 26 , Issue 2 )

Journal of Pharmacokinetics and Pharmacodynamics : Volume 26, Issue 1, February 1998

Journal of Pharmacokinetics and Pharmacodynamics : Volume 25

Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method

Content Provider	Springer Nature Link
Author	Mesnil, Florence Mentré, France Dubruc, Catherine Thét, Jean Paul Mallet, Alain
Copyright Year	1998
Abstract	A population analysis of the kinetics of mizolastine was performed from concentrations on 449 allergic patients, using the nonparametric maximum likelihood method (NPML). A two-compartment open model with zero-order absorption was used to describe the kinetics of mizolastine after oral administration. A heteroscedastic variance model was assumed for the error. To explain the kinetic variability, eight covariates were introduced in the analysis: gender, pharmaceutical dosage form, age, body weight, serum creatinine concentration, creatinine renal clearance, plasma levels of hepatic transaminases ASAT and ALAT. Their relationships to the kinetic parameters were studied by means of the estimated distribution of each kinetic parameter conditional on different levels of each covariate. An important interindividual kinetic variability was found for all parameters. Moreover, several kinetic parameters among which the duration of absorption were found to be influenced by pharmaceutical dosage form and gender. Body weight and creatinine renal clearance were found to have a little influence on the oral clearance and the smallest disposition rate constant. This population analysis was validated on a separate group of 247 other patients. For each observed concentration of this sample, a predictive distribution was computed using the individual covariates. Predicted concentrations and standardized prediction errors were deduced. The mean and variance of the standardized prediction errors were, respectively, 0.21 and 2.79. Moreover, in the validation sample, the predicted cumulative distribution function of each observed concentration was computed. Empirical distribution of these values was not significantly different from a uniform distribution, as expected under the assumption that the population model estimated by NPML is adequate.
Starting Page	133
Ending Page	161
Page Count	29
File Format	PDF
ISSN	0090466X
Journal	Journal of Pharmacokinetics and Pharmacodynamics
Volume Number	26
Issue Number	2
Language	English
Publisher	Kluwer Academic Publishers-Plenum Publishers
Publisher Date	1998-04-01
Publisher Place	New York
Access Restriction	Subscribed
Subject Keyword	Pharmacology/Toxicology Pharmacy Veterinary Medicine Biomedical Engineering Biochemistry
Content Type	Text
Resource Type	Article
Subject	Pharmacology, Toxicology and Pharmaceutics Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A Semiparametric Method for Describing Noisy Population Pharmacokinetic Data

Bayesian Nonparametric Population Models: Formulation and Comparison with Likelihood Approaches

Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients

Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling

Predictive Performance of a Semiparametric Method to Estimate Population Pharmacokinetic Parameters Using NONMEM

Bayesian Population Pharmacokinetic and Pharmacodynamic Analyses Using Mixture Models

Pitfalls in Pharmacokinetic Multicompartment Analysis

Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children

Bioavailability Assessment from Pharmacologic Data: Method and Clinical Evaluation

Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method

Similar Documents

A Semiparametric Method for Describing Noisy Population Pharmacokinetic Data

Bayesian Nonparametric Population Models: Formulation and Comparison with Likelihood Approaches

Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients

Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling

Predictive Performance of a Semiparametric Method to Estimate Population Pharmacokinetic Parameters Using NONMEM

Bayesian Population Pharmacokinetic and Pharmacodynamic Analyses Using Mixture Models

Pitfalls in Pharmacokinetic Multicompartment Analysis

Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children

Bioavailability Assessment from Pharmacologic Data: Method and Clinical Evaluation

Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method